Immunology & allergy
Immune system & allergy clinical trials
Autoimmune conditions, allergies, and disorders of the body’s immune defenses. We’re tracking 6,232 recruiting studies in this area right now.
By phase
- Not applicable3,144
- Phase 21,064
- Phase 1822
- Phase 1/Phase 2446
- Phase 3425
- Phase 4238
- Phase 2/Phase 393
Top conditions
- Multiple Sclerosis344
- Multiple Myeloma334
- Asthma194
- Lymphoma183
- Rheumatoid Arthritis141
- Type 1 Diabetes131
- Atopic Dermatitis129
- Systemic Lupus Erythematosus126
- Acute Lymphoblastic Leukemia123
- HIV Infections117
- Chronic Lymphocytic Leukemia98
- Autoimmune Diseases81
- Follicular Lymphoma73
- Diabetes Mellitus, Type 170
- Hodgkin Lymphoma67
- Leukemia64
- Rheumatoid Arthritis (RA)64
- Mantle Cell Lymphoma62
Leading sponsors
- Institute of Hematology & Blood Diseases Hospital, China91
- National Institute of Allergy and Infectious Diseases (NIAID)91
- National Cancer Institute (NCI)75
- Assistance Publique - Hôpitaux de Paris69
- Novartis Pharmaceuticals65
- M.D. Anderson Cancer Center62
- AstraZeneca57
- Mayo Clinic47
- City of Hope Medical Center46
- Memorial Sloan Kettering Cancer Center45
Where studies are running
- California492
- Maryland196
- Alabama180
- Florida142
- Arizona140
- New York122
- Massachusetts120
- Texas118
- Illinois82
- Colorado77
Recruiting studies6,232 total
- NCT02504853Recruiting
Study food allergy patterns and genetics over time
This study follows people with food allergy and some closely related or healthy people to learn how food allergy (and related conditions) develops over time. It may help researchers find causes and better ways to predict and treat food allergy.
Bethesda, MarylandAges 1 day–99 years - NCT03206099Recruiting
Genetic testing study for people linked to other NIH research
This study collects and sequences (reads) your DNA to help researchers understand health and disease. You may be invited because you are connected to another NIH study, and you must agree to testing, sample storage, and sharing de-identified genetic data for future research.
Washington D.C., District of ColumbiaAges 1 day–100 years - NCT00044122Recruiting
Study of mast cell growth in people with mastocytosis
This study looks at what causes mast cells to grow too much in people with mastocytosis. It may help researchers find better ways to diagnose or treat this condition. You can take part in person or by telehealth.
Bethesda, MarylandAges 1 day–80 years - NCT07005726Enrolling by invitationPhase 4
BCG revaccination with DTP3 to reduce infant deaths in Africa
This study tests whether giving another BCG vaccine (the one for tuberculosis) at the same time as the third DTP shot can help reduce serious infections and deaths in babies in Africa. If your baby is healthy and getting their routine DTP3, this could be an option to possibly boost their overall protection.
BissauAges 3 months–6 months - NCT06939556Recruiting
Antibody testing for the general population
This study tests a new platform to measure antibodies, which help your body fight off infections. It aims to understand how common the antibodies are in healthy adults and children.
Padova, ItalyAges 2–65 - NCT05328856Recruiting
Vital shower study to improve well-being and body regulation
This trial studies whether a special “vital shower” can improve quality of life, immune-related measures, heart/blood-pressure regulation, and overall well-being. You may be a fit if you’re generally healthy enough and can safely use the shower setup during the study.
Berlin, State of BerlinAges 18–70 - NCT01204944Recruiting
Study of people after organ or stem cell transplant
This study follows people who have had an organ transplant and/or a stem cell transplant to understand outcomes over time. You may be able to join if you agree to participate and consent to be part of the study.
ZurichAges birth–100 years - NCT06648889RecruitingPhase 2
Isatuximab for relapsed or hard-to-treat T-cell leukemia
This trial tests a drug called isatuximab for people with a type of leukemia (T-cell acute lymphoblastic leukemia) that has come back after treatment or that did not go away. Isatuximab targets a protein on the leukemia cells, which might help the immune system fight the disease.
AugsburgAges 18 years+ - NCT07132775Recruiting
Full-body electrical stimulation suit for spasticity and pain
This study tests a full-body suit that delivers gentle electrical pulses to help reduce muscle stiffness, spasms, and pain in people with conditions like multiple sclerosis, fibromyalgia, or other neurological problems. It may help with movement and comfort.
Chicago, IllinoisAges 18–75 - NCT07254364Recruiting
Wearable sensor to check insulin without needles
This study tests a wearable device that may measure insulin levels without needing blood draws. If you have type 1 diabetes, you might help researchers learn if this new sensor works for daily monitoring.
College Station, TexasAges 18–90 - NCT07793006Recruiting
New ways to diagnose lymphoma and castleman disease
This study tests new methods to diagnose lymphoma and multicentric castleman disease, which are conditions that can affect people with HIV. It may help find these diseases earlier and more accurately.
LilongweAges 1 year+ - NCT07257419RecruitingPhase 1
CAR T cells and stem cell transplant for leukemia and lymphoma
This trial tests giving special immune cells (CAR T cells) after a half-matched stem cell transplant. It's for children and young adults with high-risk leukemia or lymphoma that has come back or not responded to treatment.
Memphis, TennesseeAges Up to 21 years - NCT07075185RecruitingPhase 1
Gene therapy study for hard-to-treat multiple myeloma
This study tests a new gene therapy for people with multiple myeloma that has come back or stopped responding to at least 3 prior treatments. The therapy is designed to help your immune system fight the cancer cells more effectively.
Duarte, CaliforniaAges 18 years+ - NCT06472310Recruiting
Study of severe asthma in Russia (CORSAR)
This study looks at the health records of people in Russia with severe, uncontrolled asthma to understand their symptoms and treatments better. It does not involve any new medicine or treatment.
AstrakhanAges 18 years+ - NCT07262983RecruitingPhase 1
Baricitinib for Job syndrome with lupus or eczema
This study tests if baricitinib, a pill that changes how your immune system works, is safe and tolerable for people with Job syndrome who also have lupus-like disease or severe eczema. It might offer a new treatment option for these skin and immune problems.
Bethesda, MarylandAges 12–120 - NCT06925542RecruitingPhase 1
Study of CTX112 for adults with autoimmune disease
This trial tests an experimental cell therapy called CTX112 for people with lupus, scleroderma, or inflammatory myositis that hasn't responded well to standard treatments. The goal is to see if it's safe and if it can help control the disease.
La Jolla, CaliforniaAges 18–70 - NCT06395103RecruitingPhase 1/Phase 2
Zilovertamab vedotin for blood cancers and solid tumors
This trial tests a new drug called zilovertamab vedotin for children and young adults with certain blood cancers or solid tumors. The drug is designed to target and kill cancer cells, and the study will see if it is safe and effective.
Los Angeles, CaliforniaAges 6 months–25 years - NCT05303519RecruitingPhase 3
Safusidenib for IDH1-mutant glioma after main treatment
This Phase 3 trial tests safusidenib, a targeted medicine, to help stop or slow the return of certain brain tumors with an IDH1 mutation. It focuses on people after initial treatment (surgery and/or radiation and temozolomide), aiming to improve outcomes during maintenance therapy.
Birmingham, AlabamaAges 18 years+ - NCT00315380Recruiting
Study following people with eosinophilic granulomatosis with polyangiitis
This study looks at the health course of people who have eosinophilic granulomatosis with polyangiitis, a rare inflammatory condition. Your participation may help researchers better understand how the illness changes over time.
San Diego, CaliforniaAges Any age - NCT07067463RecruitingPhase 3
Testing orelabrutinib for primary progressive MS
This trial tests a daily pill called orelabrutinib to see if it can slow disability progression in people with primary progressive multiple sclerosis (PPMS). It may be an option for patients whose symptoms have been getting worse over the past two years.
Pheonix, ArizonaAges 18–60 - NCT06788509Enrolling by invitationPhase 1
Continued treatment and safety monitoring after a parent study
This trial allows people who were already getting study treatment in a previous trial to keep receiving it and be monitored for safety. It is designed for those who have not had serious side effects or disease worsening.
Macquarie UniversityAges 18 years+ - NCT07520006RecruitingPhase 1/Phase 2
NX-5948 With Other Drugs for B-cell Blood Cancers
This early-stage study tests a new drug called NX-5948, given alongside other cancer treatments, for adults with B-cell lymphomas and leukemias (including chronic lymphocytic leukemia, or CLL). The goal is to see if this combination helps control the disease, especially in patients whose cancer has come back or stopped responding to prior treatments.
Aurora, ColoradoAges 18 years+ - NCT06375044RecruitingPhase 1
Study of SIM0500 for relapsed or refractory multiple myeloma
This trial tests a new medication, SIM0500, for people whose multiple myeloma has returned or stopped responding to other treatments. It aims to see if the drug is safe and effective for those who have tried all standard options.
Phoenix, ArizonaAges 18 years+ - NCT07589634RecruitingPhase 2
Tocilizumab to prevent side effects from ramantamig in multiple myeloma
This study tests whether a drug called tocilizumab can prevent serious side effects (cytokine release syndrome) when combined with a new cancer drug called ramantamig. You'll be eligible if you have multiple myeloma that has come back or stopped responding to prior treatments.
Beverly Hills, CaliforniaAges 18 years+
Common questions
- How many immune system & allergy clinical trials are recruiting?
- Clin2 is tracking 6,232 recruiting immunology & allergy studies from the U.S. registry right now, out of 9,656 we cover in this area in total.
- What does “Immune system & allergy” cover here?
- Autoimmune conditions, allergies, and disorders of the body’s immune defenses. We group each study into immune system & allergy based on the conditions it studies, so you can scan the whole therapeutic area at once and drill into a specific condition.
- How do I find a immune system & allergy trial near me?
- Use the search to filter immune system & allergy studies by location and eligibility. Every Clin2 trial page explains the criteria in plain English and offers a short, optional pre-screen for a fit read — the study team makes the final decision.
Other specialties
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov; specialty groupings are derived from each study’s conditions. Talk with your doctor about whether a specific trial is right for you.